market-trends is the sole category represented across all 1 tracked stories. AACR is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Ziihera
market-trends is the sole category represented across all 1 tracked stories. AACR is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 6 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention Ziihera, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Ziihera. Shared-story counts are live from our verified record — not editorial picks.
Zymeworks Inc. has announced a series of clinical and preclinical presentations for its lead asset, Ziihera® (zanidatamab-hrii), at the 2026 AACR Annual Meeting. The data will highlight the therapeutic potential of this HER2-targeted bispecific antibody across multiple oncology indications.